Список литературы

Основные статьи

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan;3(1):1-150.Полный текст external link opens in a new window

Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012 Apr 17;156(8):570-81.Аннотация external link opens in a new window

Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73.Полный текст external link opens in a new windowАннотация external link opens in a new window

Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011 Apr 19;154(8):541-8.Полный текст external link opens in a new windowАннотация external link opens in a new window

Locatelli F, Aljama P, Canaud B, et al; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50.Полный текст external link opens in a new windowАннотация external link opens in a new window

Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62.Полный текст external link opens in a new windowАннотация external link opens in a new window

Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9(8):e1001293.Полный текст external link opens in a new windowАннотация external link opens in a new window

Статьи, указанные как источники

1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan;3(1):1-150.Полный текст external link opens in a new window

2. Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.Полный текст external link opens in a new windowАннотация external link opens in a new window

3. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003 Jan;41(1):1-12.Аннотация external link opens in a new window

4. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006 Mar 11;332(7541):563-4.Аннотация external link opens in a new window

5. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016 Jul 6;11(7):e0158765.Полный текст external link opens in a new windowАннотация external link opens in a new window

6. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 28 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59.Полный текст external link opens in a new windowАннотация external link opens in a new window

7. Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-17.Полный текст external link opens in a new windowАннотация external link opens in a new window

8. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutritional Examination Survey. Am J Kidney Dis. 1998 Dec;32(6):992-9.Аннотация external link opens in a new window

9. Freedman BI, Soucie JM, McClellan WM. Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol. 1997 Dec;8(12):1942-5.Полный текст external link opens in a new windowАннотация external link opens in a new window

10. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442-8.Полный текст external link opens in a new windowАннотация external link opens in a new window

11. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007 Oct;18(10):2644-8.Полный текст external link opens in a new windowАннотация external link opens in a new window

12. Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am. 2013 Jan;97(1):1-18.Аннотация external link opens in a new window

13. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2-7.Полный текст external link opens in a new window

14. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System, USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. 2006 [internet publication].Полный текст external link opens in a new window

15. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998 Nov 12;339(20):1448-56.Аннотация external link opens in a new window

16. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003 Apr;284(4):F863-9.Полный текст external link opens in a new windowАннотация external link opens in a new window

17. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol. 2000 Apr;278(4):F676-83.Полный текст external link opens in a new windowАннотация external link opens in a new window

18. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 Nov;60(5):850-86.Полный текст external link opens in a new windowАннотация external link opens in a new window

19. Calderon-Margalit R, Golan E, Twig G, et al. History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med. 2018 Feb 1;378(5):428-38.Полный текст external link opens in a new windowАннотация external link opens in a new window

20. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006 Aug 1;164(3):263-71.Полный текст external link opens in a new windowАннотация external link opens in a new window

21. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006 Jun;17(6):1695-702.Полный текст external link opens in a new windowАннотация external link opens in a new window

22. Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002 Sep;13(9):2363-70.Полный текст external link opens in a new windowАннотация external link opens in a new window

23. Feldman HI, Klag MJ, Chiapella AP, et al. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992 May;19(5):397-410.Аннотация external link opens in a new window

24. Helin HJ, Korpela MM, Mustonen JT, et al. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995 Feb;38(2):242-7.Аннотация external link opens in a new window

25. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005 Jan;16(1):180-8.Полный текст external link opens in a new windowАннотация external link opens in a new window

26. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995 Apr;25(4):515-33.Аннотация external link opens in a new window

27. Henrich WL, Clark RL, Kelly JP, et al. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the National Analgesic Nephropathy Study. J Am Soc Nephrol. 2006 May;17(5):1472-80.Полный текст external link opens in a new windowАннотация external link opens in a new window

28. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med. 1998 Feb 12;338(7):446-52.Аннотация external link opens in a new window

29. de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004 Dec;66(6):2109-18.Аннотация external link opens in a new window

30. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003 Oct;42(4):617-22.Аннотация external link opens in a new window

31. Montañés Bermúdez R, Gràcia García S, Pérez Surribas D, et al. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrologia. 2011;31(3):331-45.Полный текст external link opens in a new windowАннотация external link opens in a new window

32. Matsushita K, Mahmoudi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012 May 9;307(18):1941-51.Полный текст external link opens in a new windowАннотация external link opens in a new window

33. Agarwal R, Brunelli SM, Williams K, et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transpl. 2009 Mar;24(3):856-63.Аннотация external link opens in a new window

34. Collins AJ, Gilbertson DT, Snyder JJ, et al. Chronic kidney disease awareness, screening and prevention: rationale for the design of a public education program. Nephrology (Carlton). 2010 Jun;15 Suppl 2:37-42.Аннотация external link opens in a new window

35. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013 Aug 6;185(11):949-57.Полный текст external link opens in a new windowАннотация external link opens in a new window

36. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Полный текст external link opens in a new windowАннотация external link opens in a new window

37. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 Nov;3(3):259-303.Полный текст external link opens in a new window

38. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92.Полный текст external link opens in a new windowАннотация external link opens in a new window

39. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012 Apr 17;156(8):570-81.Аннотация external link opens in a new window

40. Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73.Полный текст external link opens in a new windowАннотация external link opens in a new window

41. Ku E, Glidden DV, Johansen KL, et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int. 2015 May;87(5):1055-60.Аннотация external link opens in a new window

42. Casas J, Chua W, Loukogoergakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005 Dec 10;366(9502):2026-33.Аннотация external link opens in a new window

43. Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011 Dec;22(12):2313-21.Полный текст external link opens in a new windowАннотация external link opens in a new window

44. Sinha AD, Agarwal R. ACP Journal Club. Use of >= 1 antihypertensive drug at bedtime reduced CV events more than use of all drugs in the morning in CKD. Ann Intern Med. 2012 Jun 19;156(12):JC6-8.Аннотация external link opens in a new window

45. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011 Apr 19;154(8):541-8.Полный текст external link opens in a new windowАннотация external link opens in a new window

46. Weir MR, Bakris GL, Weber MA, et al. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar;81(6):568-76.Аннотация external link opens in a new window

47. Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017 Jun 1;177(6):792-9.Аннотация external link opens in a new window

48. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31;330(13):877-84.Полный текст external link opens in a new windowАннотация external link opens in a new window

49. Clase C. Renal failure (chronic). BMJ Clin Evid. 2011 May 25;2011:2004.Полный текст external link opens in a new windowАннотация external link opens in a new window

50. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60.Полный текст external link opens in a new windowАннотация external link opens in a new window

51. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.Полный текст external link opens in a new windowАннотация external link opens in a new window

52. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31.Полный текст external link opens in a new windowАннотация external link opens in a new window

53. Balamuthusamy S, Srinivasam L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008 May;155(5):791-805.Аннотация external link opens in a new window

54. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59.Полный текст external link opens in a new windowАннотация external link opens in a new window

55. Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13.Полный текст external link opens in a new windowАннотация external link opens in a new window

56. Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2011 Mar;20(2):146-52.Аннотация external link opens in a new window

57. Jablonski KL, Chonchol M. Cardiovascular disease: should statin therapy be expanded in patients with CKD? Nat Rev Nephrol. 2012 Jul 3;8(8):440-1.Аннотация external link opens in a new window

58. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):263-75.Полный текст external link opens in a new windowАннотация external link opens in a new window

59. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):251-62.Аннотация external link opens in a new window

60. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014 May 31;(5):CD007784.Полный текст external link opens in a new windowАннотация external link opens in a new window

61. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289.Полный текст external link opens in a new windowАннотация external link opens in a new window

62. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun;65(6):1991-2002.Аннотация external link opens in a new window

63. Segura J, García-Donaire JA, Ruilope LM. Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S64-6.Полный текст external link opens in a new windowАннотация external link opens in a new window

64. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.Аннотация external link opens in a new window

65. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 Nov 16;355(20):2071-84.Аннотация external link opens in a new window

66. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32.Аннотация external link opens in a new window

67. KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012 Aug;2(4):279-335.Полный текст external link opens in a new window

68. Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013 Jan;61(1):44-56.Аннотация external link opens in a new window

69. Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul;66(1):69-74.Аннотация external link opens in a new window

70. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1-59.Полный текст external link opens in a new window

71. Coyne DW, Goldberg S, Faber M, et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6.Полный текст external link opens in a new windowАннотация external link opens in a new window

72. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013 Oct 12;382(9900):1268-77.Аннотация external link opens in a new window

73. Association for Vascular Access, American Society of Diagnostic and Interventional Nephrology. Preservation of peripheral veins in patients with chronic kidney disease. Mar 2011 [internet publication].Полный текст external link opens in a new window

74. Susantitaphong P, Sewaralthahab K, Balk EM, et al. Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol. 2012;35(6):540-7.Аннотация external link opens in a new window

75. National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Jan 2007 [internet publication].Полный текст external link opens in a new window

76. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009 Feb;53(2):197-207.Аннотация external link opens in a new window

77. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167.Аннотация external link opens in a new window

78. O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med. 2012 Feb;15(2):228-35.Полный текст external link opens in a new windowАннотация external link opens in a new window

79. Blake PG, Bargman JM, Brimble KS, et al; Canadian Society of Nephrology Work Group on Adequacy of Peritoneal Dialysis. Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011. Perit Dial Int. 2011 Mar-Apr;31(2):218-39.Аннотация external link opens in a new window

80. Berdud I, Arenas MD, Bernat A, et al; Grupo de Trabajo de Hemodiálisis Extrahospitalaria (Outpatient Haemodialysis Group). Appendix to dialysis centre guidelines: recommendations for the relationship between outpatient haemodialysis centres and reference hospitals. Opinions from the Outpatient Dialysis Group. Grupo de Trabajo de Hemodiálisis Extrahospitalaria. Nefrologia. 2011;31(6):664-9.Полный текст external link opens in a new windowАннотация external link opens in a new window

81. Clase CM, Smyth A. Chronic kidney disease: diet. BMJ Clin Evid. 2015 Jun 29;2015:2004.Полный текст external link opens in a new windowАннотация external link opens in a new window

82. Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12.Полный текст external link opens in a new windowАннотация external link opens in a new window

83. Liu Z, Su G, Guo X, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev. 2015 Sep 16;(9):CD010350.Полный текст external link opens in a new windowАннотация external link opens in a new window

84. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009 Jul;5(7):375-83.Аннотация external link opens in a new window

85. Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015 Dec 3;9:6275-83.Полный текст external link opens in a new windowАннотация external link opens in a new window

86. Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018 Jun;42(3):188-95.Полный текст external link opens in a new windowАннотация external link opens in a new window

87. Leporini C, Pisano A, Russo E, et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res. 2016 May;107:315-32.Аннотация external link opens in a new window

88. Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2012 May 28;172(10):761-9.Полный текст external link opens in a new windowАннотация external link opens in a new window

89. Jing Z, Wei-jie Y, Nan Z, et al. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One. 2012;7(8):e43655.Полный текст external link opens in a new windowАннотация external link opens in a new window

90. Albaramki J, Hodson EM, Craig JC, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD007857.Полный текст external link opens in a new windowАннотация external link opens in a new window

91. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.Аннотация external link opens in a new window

92. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584-90.Полный текст external link opens in a new windowАннотация external link opens in a new window

93. Carrera F, Lok CE, de Francisco A, et al; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010 Dec;25(12):4009-17.Полный текст external link opens in a new windowАннотация external link opens in a new window

94. Locatelli F, Aljama P, Canaud B, et al; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50.Полный текст external link opens in a new windowАннотация external link opens in a new window

95. Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62.Полный текст external link opens in a new windowАннотация external link opens in a new window

96. Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinol. 2012 Apr 1;4(2):118-27.Полный текст external link opens in a new windowАннотация external link opens in a new window

97. National Kidney Foundation. KDOQI clinical practice guidelines: nutrition in chronic renal failure. Am J Kidney Dis. 2000 Jun;35(6 Suppl 2):S1-140.Полный текст external link opens in a new windowАннотация external link opens in a new window

98. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998 Nov;32(5):853-906.Аннотация external link opens in a new window

99. KDOQI Workgroup. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153.Полный текст external link opens in a new windowАннотация external link opens in a new window

100. Molitoris BA, Froment DH, Mackenzie TA. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. 1989 Dec;36(6):949-53.Аннотация external link opens in a new window

101. Warnock DG. Uremic acidosis. Kidney Int. 1988 Aug;34(2):278-87.Аннотация external link opens in a new window

102. Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9(8):e1001293.Полный текст external link opens in a new windowАннотация external link opens in a new window

Использование этого контента попадает под действие нашего заявления об отказе от ответственности